Peripheral neuropathy is one of the most common complications of diabetes mellitus. Using a mouse model of diabetic peripheral neuropathy, we tested the hypothesis that thymosin β4 (Tβ4) ameliorates diabetesinduced neurovascular dysfunction in the sciatic nerve and promotes recovery of neurological function from diabetic peripheral neuropathy. Tβ4 treatment of diabetic mice increased functional vascular density and regional blood flow in the sciatic nerve, and improved nerve function. Tβ4 upregulated angiopoietin-1 (Ang1) expression, but suppressed Ang2 expression in endothelial and Schwann cells in the diabetic sciatic nerve. In vitro, incubation of Human Umbilical Vein Endothelial Cells (HUVECs) with Tβ4 under high glucose condition completely abolished high glucose-downregulated Ang1 expression and high glucose-reduced capillary-like tube formation. Moreover, incubation of HUVECs under high glucose with conditioned medium collected from Human Schwann Cells (HSCs) treated with Tβ4 significantly reversed high glucose-decreased capillary-like tube formation. PI3K/Akt signaling pathway is involved in Tβ4-regulated Ang1 expression on endothelial and Schwann cells. These data indicate that Tβ4 likely acts on endothelial cells and Schwann cells to preserve and/ or restore vascular function in the sciatic nerve which facilitates improvement of peripheral nerve function under diabetic neuropathy. Thus, Tβ4 has potential for the treatment of diabetic peripheral neuropathy.
Introduction
Peripheral neuropathy is one of the most common and disabling complications of diabetes mellitus. Studies of diabetic peripheral neuropathy from experimental animals and humans indicate that the development of diabetic neuropathy is closely associated with marked neurovascular dysfunction (Cameron et al., 2001; Ebenezer et al., 2011; Tesfaye et al., 1993) . Vascular dysfunction precedes the appearance of nerve conduction velocity deficits, leading to nerve damage (Cameron and Cotter, 1999; Cameron et al., 2005; Ebenezer et al., 2011) . Therapies targeting neurovascular function have been shown to restore nerve function in experimental diabetic peripheral neuropathy (Ii et al., 2005; Kusano et al., 2004; Schratzberger et al., 2001) .
Thymosin Beta4 (Tβ4), a small 4.9 kDa polypeptide of 43 amino acids, is a major intracellular G-actin-sequestering peptide (Goldstein et al., 1996) and is present in almost all cell types (Crockford et al., 2010) . Tβ4 has multiple biological functions that include promoting diabetic wound healing by repairing and regenerating damaged tissues (Philp et al., 2003) and enhancing angiogenesis after myocardial infarction and vasculogenesis during development (Crockford, 2007; Smart et al., 2007a) . Tβ4 is currently under a phase II clinical trial for the treatment of patients with acute myocardial infarction (ClinicalTrials.gov, http:// clinicaltrials.gov/ct2/show/NCT01311518; Ruff et al., 2010). In the central nervous system, preclinical studies show that Tβ4 has neuroprotective and neurorestorative effects by reducing neuronal damage and enhancing oligodendrogenesis, which lead to improvement of neurological outcomes after stroke, traumatic brain injury and multiple sclerosis (Morris et al., 2010; Philp et al., 2003; Xiong et al., 2011; Zhang et al., 2009) . However, the effect of Tβ4 on peripheral nerves, such as diabetic peripheral neuropathy, has not been invetigated.
The angiopoietins (Ang1 and Ang2) and their receptor Tie-2 regulate vascular development and homeostasis (Suri et al., 1996; Teichert-Kuliszewska et al., 2001) . Ang-1 promotes vascular stabilization and maturation whereas Ang2 acts as a partial agonist or antagonist of Ang1 signaling, depending on vascular endothelial growth factor (VEGF) bioavailability (Maisonpierre et al., 1997; Suri et al., 1996; Thebaud et al., 2005) . The Ang/Tie2 signaling pathway plays an important role in mediating vascular function under diabetes (Chen and Stinnett, 2008b; Tuo et al., 2008) . Hyperglycemia downregulates Ang1 and upregulates Ang2, which exacerbates myocardial infarction (Morris et al., 2010; Tuo et al., Neurobiology of Disease 48 (2012) 546-555 
